RE: testing..22 Feb 2022 06:36
We proved it works with all other variants and better than all other tests. It was the antibody that let us down, so I don’t see how it effects the platform, especially since BAMS and Elisa also showed the quality of Affimers. At what point to the stop spending money on something that will bring very little or no revenue back? I’d say keep the cash for Ava6000 for now and continue funding DX as a future op. As was discussed yesterday there is very little appetite for private testing amongst a population who’ve been treated to the full one rule for us agenda.